This study provides mechanistic insight into early mitochondrial dysfunction in AD and identifies the Aβ‐Me3 axis, which functions not only as a metabolic responder to Aβ‐associated stress but also as a contributor to early mitochondrial pathology.
Abstract
Mitochondrial dysfunction is one of the earliest pathological features of Alzheimer's disease (AD), preceding overt neurodegeneration and cognitive decline. Amyloid‐β (Aβ) accumulation has long been considered a central pathogenic event in AD, yet how Aβ toxicity is mechanistically linked to mitochondrial impairment during early disease stages remains incompletely understood. To address this, we combined multi‐omics with in vivo and in vitro genetic interventions. Here, we show that malic enzyme 3 (Me3) links Aβ aggregation to mitochondrial dysfunction in APP/PS1 mice and neuronal cells. At ultra‐early and early AD stages (3 and 6 months), Me3 was upregulated and accumulated within mitochondria, where it colocalized with Aβ42 and physically interacted with it, an association linked to oxidative stress and impaired mitophagy. Knockdown of Me3 reduced mitochondrial reactive oxygen species, improved mitochondrial morphology, and alleviated mitophagy defects in both cellular and mouse models, with statistical significance across these functional measurements (p < 0.05). These results suggest that Me3 functions not only as a metabolic responder to Aβ‐associated stress but also as a contributor to early mitochondrial pathology. By identifying the Aβ‐Me3 axis, this study provides mechanistic insight into early mitochondrial dysfunction in AD, while further validation in human AD samples remains necessary.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which microglia-mediated neuroinflammation contributes to disease progression. Icariin (ICA), a major bioactive flavonoid from Epimedium, has neuroprotective activity, but how it regulates mitochondrial quality control and inflammatory injury in mi...
Long-Min Fan, Hai-Tao Jiang, Min Yi et al.· Chinese Journal of Natural M...· 0 citations
Overall, MA-5 suppresses neuroinflammation and reverses accelerated transcriptomic aging, supporting its potential as a therapeutic strategy for GD and other lysosomal storage disorders, as well as for diseases characterized by mitochondrial dysfunction, chronic inflammation, and pathological accumulation.
Y. Tongu, Tomoko Kasahara, Kohta Nakamura et al.· Research Square· 0 citations
Recent findings regarding the pathogenic roles of β-amyloid and α-synuclein in AD and PD are summarized, as well as the protective effects offered by regulating mitophagy and inflammasome activity.
Wei Long, Mengqin Yuan, Sirui Wang et al.· Translational Neurodegenerat...· 0 citations
Parkinson's disease (PD) is a prevalent age-related neurodegenerative disorder characterized by pathological α-synuclein aggregation, mitochondrial dysfunction, and progressive loss of dopaminergic neurons, with no effective disease-modifying treatment available. Sephin1 has been proven to exert protective effects in m...
Xv-shen Ding, Bao Wang, Zheng Han et al.· Biochemical Pharmacology· 0 citations
Findings in this study highlight the coordinated dysregulation of the FMA axis in AD and provide a computational basis for exploring multi-target therapeutic strategies.
This work describes LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluates its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD), supporting TRPML1 agonism as a promising strategy to counterac...
V. Cullen, Jun-Sheng Yang, Xiang-Yang Yu et al.· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.